Cagrilintide (AM833) Cagrilintide is a long-acting amylin analog designed for once-weekly (OW) SC administration (based on the structure of natural amylin), developed by Novo Nordisk [112]
However, the substitution of Ile 12 with Ala remarkably decreased activity
While trials used 6 mg, 12 mg, and 36 mg doses, Lilly conducted pharmacokinetic studies to establish equivalent doses of 9 mg, 14.5 mg, and 17.2 mg for manufacturing
Presently, the Australian Diabetes Society (ADS) and ANZCA Perioperative Diabetes and Hyperglycaemia Guidelines (November 2022) provide the universal recommendation to withhold all non-insulin antihyperglycaemics on day of surgery, including GLP-1 agonists, with SGLT2 inhibitors to be withheld 2 days prior to surgery
Time to exhaustion was negatively associated with fat mass (r = 0.91) but not with LBM (r = 0.12)
Precedent exists: insulin was treated as a luxury good until public outcry and generic competition forced prices down